Managing your weight in middle age can be remarkably frustrating, especially when habits that used to work suddenly stop moving the needle. Shifting estrogen levels during perimenopause and postmenopause trigger natural biological changes that encourage the body to store stubborn visceral fat around the midsection.
Fortunately, clinical findings presented at the autumn 2026 European Association for the Study of Diabetes (EASD) meeting in Milan offer encouraging news for women navigating these metabolic transitions. Research highlighted Eli Lilly’s oral GLP-1 receptor agonist, orforglipron (marketed as Foundayo), showing it was just as effective for premenopausal women as for those in perimenopause and postmenopause. In a combined analysis of the ATTAIN-1 and ATTAIN-2 clinical trials, participants experienced an average weight reduction of roughly 14%.
Foundayo is attracting major clinical interest because it delivers the metabolic benefits of GLP-1 medications in a straightforward daily pill – completely free from the strict food, liquid or refrigeration rules that often complicate other regimens. Approved earlier this year in the U.S. for chronic weight management in adults with obesity or overweight alongside weight-related conditions, the medication is quickly emerging as a practical alternative to injections.
Most encouragingly for those targeted belly changes, the study revealed that the pill helped women trim up to 12.5 centimeters (about 5 inches) from their waistlines, regardless of their menopausal stage.
Is Foundayo good for weight loss?
Tunde Rasheed, B.Sc. Researcher in Chemical and Polymer Medical Engineering, tells Blavity Health, “Yes, strong multi-phase clinical trial data show that Foundayo is very effective for body fat redistribution and chronic weight management. Adults with overweight or obesity, both with and without type 2 diabetes, lost significant amounts of overall body mass in the 72-week ATTAIN-1 and ATTAIN-2 trials, respectively. In both studies, women in the premenopausal, perimenopausal and postmenopausal groups lost up to 14% average total body weight.”
In addition to an overall reduction in scale weight, Foundayo achieved clinically significant changes in visceral adiposity. Waist circumference decreased by up to 12.5 centimeters (approximately 5 inches), and waist-to-height ratios improved significantly for all participants across all hormonal stages. As for milestone benchmarks, up to 83% of women taking orforglipron lost at least 5% of their initial body weight, while only 30% of women taking the placebo pill did. PubMed Central findings note that endocrinologists widely accept that a weight loss of at least 5% of total body weight is required for a clinical reduction in systemic blood pressure and insulin resistance, and for an optimal cardiovascular lipid profile.
How Foundayo works
According to Eli Lilly, Foundayo is a non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist that selectively mimics the action of the endocrine satiety hormones.
Orforglipron is a synthetic small molecule that is not destroyed by digestive enzymes in the gut when swallowed, unlike natural GLP-1 and peptide-based drugs. This means that the active drug can be easily absorbed from the digestive system into the systemic circulation without the need for special absorption enhancers, extended fasting or restrictions on water intake.
After entering circulation, the drug acts directly on GLP-1 receptors in the pancreas, gastrointestinal tract and the brainstem region responsible for appetite control. It slows stomach movement, which decreases the speed at which food physically enters the small intestine and makes a person feel full after eating.
In the brain, it enters the arcuate nucleus of the hypothalamus, which silences the brain’s constant chatter about food, dampens the hunger signal and lowers the baseline calorie drive. At the same time, it promotes glucose-stimulated insulin secretion by pancreatic beta cells. It inhibits the release of inappropriately high levels of liver glucagon, thus providing stable postprandial blood sugar levels.
Common side effects
Foundayo’s ability to slow stomach emptying and recalibrate metabolic signals can lead to common digestive side effects, especially when starting or increasing the dose.
The most common side effect is mild to moderate nausea, usually in the first weeks of treatment or after a dose increase, and is often associated with early satiety, indigestion and slight acid reflux (which may be temporary and resolve quickly by reducing meal size).
Loose stools or diarrhea are common as the gastrointestinal tract adjusts to altered gut peptide signals, and are often accompanied by mild constipation due to impaired gastric emptying.
Rare or serious side effects
Although the drug is considered safe when used under a licensed health care professional’s supervision and monitoring, tweaking systemic gut hormone pathways has potential high-acuity clinical risks.
Acute pancreatitis is a rare but serious condition, characterized by the sudden onset of severe abdominal pain that feels like it is located in the back and cannot be relieved by medication.
Acute gallbladder disease, such as cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder), can develop rapidly and is largely due to the rapid mobilization of adipose tissue (fat) and changes in biliary cholesterol saturation during significant weight loss, according to DailyMed.
Hypoglycemia is a potentially life-threatening clinical risk factor when Foundayo is administered concurrently with insulin or insulin secretagogues (such as sulfonylureas) in patients with type 2 diabetes and must be actively managed with dose reduction of any other antidiabetic drug being used at the same time.
If vomiting and diarrhea continue without proper oral fluid and electrolyte replacement, severe dehydration with acute kidney injury may ensue.
Pulmonary aspiration during surgery or deep procedural sedation is a new safety concern for all GLP-1 therapies, as gastric emptying is delayed; therefore, it is important to communicate with anesthesiology teams before elective procedures.
What to do if you notice symptoms
To effectively manage side effects while on Foundayo, it is important to make purposeful dietary changes and to keep an open line of communication with your prescribing healthcare providers.
For mild to moderate nausea, cut down on how much you eat right away, chew food thoroughly and choose bland, lean protein foods, avoiding those high in fat, ultra-processed foods, and greasy foods, since they can make the nausea worse. Prevent secondary fluid loss due to diarrhea by drinking plenty of water, clear broth and electrolyte fluids.
Stop the drug right away and get help if the pain is severe and steady and spreads to the middle of the back, if vomiting causes you to lose fluids for over 24 hours, if your eyes or skin are yellow or if you have symptoms of low blood sugar (tremors, cold sweats).
How much does Foundayo cost?
The out-of-pocket cost of Foundayo depends on health insurance formulary coverage, distribution pathways and manufacturer assistance programs.
The cash price is approximately $149 per month for the lowest 0.8 mg starting dose and $199 per month for intermediate doses for commercial self-pay patients who purchase directly from LillyDirect or an accredited digital health company. There are manufacturer direct-pay programs, and higher maintenance doses typically cost $299–$349 per month.
For the commercial health insurance plan patient, the copay is as low as $25 per month with the manufacturer’s savings card if the drug company is on the health insurance plan’s formulary. But coverage requirements often include documentation of a qualifying baseline BMI (usually 30 or above or 27 in the presence of an underlying weight-related health condition, such as hypertension or dyslipidemia), prior authorization and step-therapy trials of older medications.
Alternatives
There are multiple pharmacologic, behavioral, and surgical options for patients seeking evidence-based support for weight management tailored to their clinical needs.
The direct pharmacologic treatment options are injections of GLP-1 receptor agonists, such as injectable semaglutide, or dual GIP/GLP-1 receptor agonists, such as injectable tirzepatide, with an average weight loss of 15% to 21%, per Healthline. There are also daily oral semaglutide tablets that work the same way and are just as effective at providing GLP-1 coverage for those who prefer this route.
Older weight-loss drugs, such as phentermine-topiramate (Qsymia), bupropion-naltrexone (Contrave), and generic orlistat, work through mechanisms other than GLP-1 and produce 5% to 10% weight loss.
Whether or not pharmacological therapy is used, complementary lifestyle foundations, such as promoting progressive resistance exercise to help maintain lean skeletal muscle mass and a high-protein, plant-rich Mediterranean diet, are critical to a long-term metabolic health strategy.
What to eat when taking Foundayo
Foundayo is an oral small molecule pill that can be administered at any time of the day, with or without food, unlike the first generation of oral GLP-1s, which had to be taken as soon as the patient rose in the morning with a few sips of plain water and did not eat for 30 minutes after. Pick a time each day to establish a routine, such as breakfast, dinner, or something else you already do.
Adjusting your diet to your individual needs is essential for optimizing fat loss, maintaining muscle mass and reducing gastrointestinal side effects when using an oral GLP-1.
Eat good quality lean protein foods at every meal, including skinless chicken breast, wild fish, tofu, egg whites, low-fat Greek yogurt and legumes. Appetite is reduced, and total calories consumed will naturally decrease; therefore, eating enough protein (about 1.0 to 1.5 g per kg of ideal body weight per day) will prevent the breakdown of valuable skeletal muscle.
Prevent constipation by eating soluble and insoluble dietary fiber from gentle, nutrient-dense foods such as oatmeal, cooked vegetables, berries and chia seeds. Avoid large portions, fatty, fried, or sweet foods, as dietary fat slows stomach emptying even further, which can cause intense nausea and bloating.
Last but not least, try to keep fluids going all day long – drink water and electrolyte broths between meals to avoid overfilling the tummy during a meal.
“People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment,” says Deborah Horn, DO, MPH, FOMA, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston.
Bottom line
The needle-free, once-daily oral GLP-1 drug Foundayo (orforglipron) is a breakthrough in chronic weight management, leading to an average weight loss of up to 14% in women, regardless of menopausal status. The drug directly reduces high-risk abdominal fat that tends to build up during the hormonal shifts that happen in the middle years by as much as 5 inches, according to the results. When combined with a high-protein diet and resistance training, Foundayo is an effective and convenient therapeutic tool for long-term metabolic health, provided it is used alongside regular medical monitoring for your best self.
Frequently Asked Questions
What is the most successful weight loss pill?
Modern small-molecule oral GLP-1 receptor agonists like Foundayo (orforglipron) and high-dose oral semaglutide represent the most successful weight-loss pills available, delivering double-digit average weight reductions that significantly exceed those of older non-GLP-1 oral medications.
Is Foundayo the same as Ozempic?
No, Foundayo is a once-daily oral tablet containing the small-molecule drug orforglipron, developed specifically for weight loss. In contrast, Ozempic is a once-weekly injectable medication containing semaglutide, approved primarily for the treatment of type 2 diabetes.
Citations
Diabetes UK. September 2026 research highlights from Europe’s largest diabetes conference. Diabetes UK. October 7, 2026. https://www.diabetes.org.uk/about-us/news-and-views/september-research-highlights-europes-largest-diabetes-conference
Schimelpfening N. Oral GLP-1 Orforglipron (Foundayo) Achieves Weight Loss for Women of All Ages. Healthline. October 6, 2026. https://www.healthline.com/health-news/oral-glp-1-orforglipron-foundayo-uniform-weight-loss-women
Ryan DH, Yockey SR. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and over. Current Obesity Reports. 2017;6(2):187-194. doi:10.1007/s13679-017-0262-y
Eli Lilly. FDA approves Lilly’s FoundayoTM (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions | Eli Lilly and Company. Eli Lilly and Company. 2025. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
DailyMed. These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral useInitial U.S. Approval: 2026. Nih.gov. 2026. https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62